We are the go to experts in the region for strategic pricing and access for innovative therapies. Our team is passionate about science and have an unwavering focus on patients - your access is our success.
Our job is to push the boundaries of traditional launch sequencing and consider how regional launches within the Middle East and Africa can result in commercial success not just in our region, but also at a global level:
Our proprietary analysis frameworks alongside our unparalleled network in the region are the recipe for our success. Whether it's tender managers from NUPCO in Saudi Arabia, private insurance formulary managers in South Africa, or underwriters for Daman in the UAE, we have access to the most senior of decision makers in the Middle East & Africa to share their insights on the latest developments in the region.
Number of
consulting projects
Hours of payers and
KOL interviews conducted
I moved to the region at a time where many drugs that were available in Europe were not available to us, even 3 years after EMA approval. We're at a tipping point now where the regulatory frameworks and supportive pricing policies have enabled pharma and biotech companies to shift to launching in our region earlier than ever before. It is my mission to ensure that no country in our region is left behind and that access is granted broadly and quickly, to every single patient, no matter where they are born.
